Groupe Francophone Des Myelodysplasies
Clinical trials sponsored by Groupe Francophone Des Myelodysplasies, explained in plain language.
-
New combo therapy aims to boost red blood cells in MDS patients
Disease control Recruiting nowThis study tests a combination of two drugs—luspatercept and erythropoietin (EPO)—for people with a low-risk form of myelodysplastic syndrome (MDS) that does not involve ring sideroblasts. Participants must have already tried EPO alone without success or be unable to take it. The…
Phase: PHASE1, PHASE2 • Sponsor: Groupe Francophone des Myelodysplasies • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New drug hope for rare inflammatory VEXAS syndrome
Disease control Recruiting nowThis phase 2 trial tests the drug momelotinib in 57 people with VEXAS syndrome, a rare inflammatory condition that may also involve a bone marrow disorder called MDS. Participants receive momelotinib daily, and doctors check if symptoms improve and if steroid doses can be lowered…
Phase: PHASE2 • Sponsor: Groupe Francophone des Myelodysplasies • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC